» Articles » PMID: 34475155

Expectation-induced Enhancement of Pain, Itch and Quality of Life in Psoriasis Patients: Study Protocol of a Randomised Controlled Trial

Overview
Journal BMJ Open
Specialty General Medicine
Date 2021 Sep 3
PMID 34475155
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Experimental and clinical data demonstrate that skin diseases like psoriasis are affected by psychological factors and can be modulated by interventions other than conventional drug therapy. The expectation of patients towards the benefit of a forthcoming treatment as well as treatment pre-experiences have been demonstrated as crucial factors mediating placebo responses in inflammatory skin diseases. However, it is unknown whether and to what extent treatment outcomes of psoriasis patients under therapy with monoclonal antibodies like secukinumab can be experimentally modulated at subjective and physiological levels by modifying the expectation of patients via verbal instruction or prior experience.

Methods And Analysis: Treatment expectations will be modulated in patients with moderate-to-severe psoriasis undergoing treatment with the anti-interleukin-17A monoclonal antibody secukinumab. Patients with a Psoriasis Area and Severity Index (PASI) >12 will be randomly allocated to one of three groups (N=40 each). As a standard schedule, patients in the pharmacological control group (group 1) will be treated weekly with 300 mg secukinumab, while patients in groups 2 and 3 will receive only 75 mg secukinumab (75% dose reduction) during all treatment weeks. In addition to the injections, patients in group 3 will ingest a novel tasting drink, with a cover story explaining that previous studies showed additional beneficial effects of this combination (drug and drink). Patients will be assessed and treated at nine visits over a 16-week period, during which the severity of pain and itch symptoms, skin lesions and quality of life will be analysed with standardised questionnaires and the PASI.

Ethics And Dissemination: This study was approved by the Ethics committee of the Medical Faculty of the University Duisburg-Essen. Study outcomes will be published in peer-reviewed scientific journals.

Citing Articles

Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients.

Holsken S, Krefting F, Muhlhaus S, Bese D, Schedlowski M, Sondermann W Psoriasis (Auckl). 2025; 15():9-22.

PMID: 39810930 PMC: 11731016. DOI: 10.2147/PTT.S486338.


"I Was Almost in Disbelief" - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab.

Holsken S, Benthin C, Krefting F, Muhlhaus S, Nestoriuc Y, Schedlowski M Patient Prefer Adherence. 2024; 18:1299-1310.

PMID: 38947870 PMC: 11213235. DOI: 10.2147/PPA.S458643.


Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C Cochrane Database Syst Rev. 2023; 7:CD011535.

PMID: 37436070 PMC: 10337265. DOI: 10.1002/14651858.CD011535.pub6.


Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C Cochrane Database Syst Rev. 2022; 5:CD011535.

PMID: 35603936 PMC: 9125768. DOI: 10.1002/14651858.CD011535.pub5.


Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.

Damiani G, Odorici G, Pacifico A, Morrone A, Conic R, Davidson T Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056153 PMC: 8780469. DOI: 10.3390/ph15010095.

References
1.
Rutherford B, Wall M, Brown P, Choo T, Wager T, Peterson B . Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials. Am J Psychiatry. 2016; 174(2):135-142. PMC: 5288269. DOI: 10.1176/appi.ajp.2016.16020225. View

2.
Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke W . The role of IL-23 and the IL-23/T 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(10):1616-1626. PMC: 5697699. DOI: 10.1111/jdv.14433. View

3.
Papoiu A, Wang H, Coghill R, Chan Y, Yosipovitch G . Contagious itch in humans: a study of visual 'transmission' of itch in atopic dermatitis and healthy subjects. Br J Dermatol. 2011; 164(6):1299-303. PMC: 3110738. DOI: 10.1111/j.1365-2133.2011.10318.x. View

4.
Papp K, Langley R, Sigurgeirsson B, Abe M, Baker D, Konno P . Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2012; 168(2):412-21. DOI: 10.1111/bjd.12110. View

5.
Pecina M, Zubieta J . Molecular mechanisms of placebo responses in humans. Mol Psychiatry. 2014; 20(4):416-23. PMC: 4372496. DOI: 10.1038/mp.2014.164. View